Advertisement
UK markets close in 6 hours 22 minutes

  • FTSE 100

    7,819.73
    -57.32 (-0.73%)
     

  • FTSE 250

    19,265.79
    -184.88 (-0.95%)
     

  • AIM

    740.54
    -4.75 (-0.64%)
     

  • GBP/EUR

    1.1681
    -0.0002 (-0.02%)
     

  • GBP/USD

    1.2447
    +0.0008 (+0.07%)
     

  • Bitcoin GBP

    51,863.07
    +2,523.66 (+5.11%)
     

  • CMC Crypto 200

    1,329.83
    +17.20 (+1.31%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    83.16
    +0.43 (+0.52%)
     

  • GOLD FUTURES

    2,399.20
    +1.20 (+0.05%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,669.85
    -167.55 (-0.94%)
     

  • CAC 40

    7,959.41
    -63.85 (-0.80%)
     
Money:

11 beautiful homes with glorious garden rooms

Why a garden room can add value to a home

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2017

GlobeNewswire

Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2017

(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (March 6, 2017 - 6.00 p.m.) - As of February 28, 2017, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

February 28, 2017

Shares outstanding

218,530,045

Exercisable voting rights

233,082,728

Total voting rights, based on all outstanding shares,
including shares stripped of their voting rights*

235,128,468

(*) Shares held by the Company.

ADVERTISEMENT

About Essilor
The world`s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world. For more information, please visit www.essilor.com.
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

------------------------

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16

PDF Version of the news release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Essilor International via GlobeNewswire
HUG#2085065